Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/223113
Title: | The Multifaceted Role of Growth Differentiation Factor 15 (GDF15): A Narrative Review from Cancer Cachexia to Target Therapy |
Author: | Filippini, Daria Maria Romaniello, Donatella Carosi, Francesca Fabbri, Laura Carlini, Andrea Giusti, Raffaele Maio, Massimo di Alfieri, Salvatore Lauriola, Mattia Pantaleo, Maria A. Arribas, Lorena Oliva Bernal, Marc Bossi, Paolo Locati, Laura Deborah |
Keywords: | Marcadors tumorals Oncologia Tumor markers Oncology |
Issue Date: | 8-Aug-2025 |
Publisher: | MDPI |
Abstract: | Background: Growth Differentiation Factor 15 (GDF15) has emerged as a key biomarker and therapeutic target in oncology, with roles extending beyond cancer cachexia. Elevated GDF15 levels correlate with poor prognosis across several solid tumors, including colorectal, gastric, pancreatic, breast, lung, prostate, and head and neck cancers. GDF15 modulates tumor progression through PI3K/AKT, MAPK/ERK, and SMAD2/3 signaling, thereby promoting epithelial-to-mesenchymal transition, metastasis, immune evasion, and chemoresistance via Nrf2 stabilization and oxidative stress regulation. Methods: We performed a narrative review of the literature focusing on the role of GDF15 in solid tumors, with a particular emphasis on head and neck cancers. Results: In head and neck squamous cell carcinoma (HNSCC), GDF15 overexpression is linked to aggressive phenotypes, radioresistance, poor response to induction chemotherapy, and failure of immune checkpoint inhibitors (ICIs). Similar associations are observed in colorectal, pancreatic, and prostate cancer, where GDF15 contributes to metastasis and therapy resistance. Targeting the GDF15-GFRAL axis appears therapeutically promising: the monoclonal antibody ponsegromab improved cachexia-related outcomes in the PROACC-1 trial, while visugromab combined with nivolumab enhanced immune response in ICI-refractory tumors. Conclusions: Further investigation is warranted to delineate the role of GDF15 across malignancies, refine patient selection, and evaluate combinatorial approaches with existing treatments. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/biomedicines13081931 |
It is part of: | Biomedicines, 2025, vol. 13, num. 8, 1931 |
URI: | https://hdl.handle.net/2445/223113 |
Related resource: | https://doi.org/10.3390/biomedicines13081931 |
ISSN: | 2227-9059 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
biomedicines-13-01931.pdf | 1.68 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License